These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1631 related articles for article (PubMed ID: 28976959)

  • 21. CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy.
    Ashraf MU; Salman HM; Khalid MF; Khan MHF; Anwar S; Afzal S; Idrees M; Chaudhary SU
    Biomed Pharmacother; 2021 Apr; 136():111239. PubMed ID: 33454599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmable Inhibition and Detection of RNA Viruses Using Cas13.
    Freije CA; Myhrvold C; Boehm CK; Lin AE; Welch NL; Carter A; Metsky HC; Luo CY; Abudayyeh OO; Gootenberg JS; Yozwiak NL; Zhang F; Sabeti PC
    Mol Cell; 2019 Dec; 76(5):826-837.e11. PubMed ID: 31607545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A New Method for Programmable RNA Editing Using CRISPR Effector Cas13X.1.
    Li L; Liu W; Zhang H; Cai Q; Wen D; Du J; Sun J; Li L; Gao C; Lin P; Wu M; Jiang J
    Tohoku J Exp Med; 2023 May; 260(1):51-61. PubMed ID: 36823185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure and engineering of the minimal type VI CRISPR-Cas13bt3.
    Nakagawa R; Kannan S; Altae-Tran H; Takeda SN; Tomita A; Hirano H; Kusakizako T; Nishizawa T; Yamashita K; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2022 Sep; 82(17):3178-3192.e5. PubMed ID: 36027912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells.
    Méndez-Mancilla A; Wessels HH; Legut M; Kadina A; Mabuchi M; Walker J; Robb GB; Holden K; Sanjana NE
    Cell Chem Biol; 2022 Feb; 29(2):321-327.e4. PubMed ID: 34343484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Composition and Diversity of CRISPR-Cas13a Systems in the Genus
    Watanabe S; Cui B; Kiga K; Aiba Y; Tan XE; Sato'o Y; Kawauchi M; Boonsiri T; Thitiananpakorn K; Taki Y; Li FY; Azam AH; Nakada Y; Sasahara T; Cui L
    Front Microbiol; 2019; 10():2838. PubMed ID: 31921024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing.
    Adler BA; Hessler T; Cress BF; Lahiri A; Mutalik VK; Barrangou R; Banfield J; Doudna JA
    Nat Microbiol; 2022 Dec; 7(12):1967-1979. PubMed ID: 36316451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing.
    Fiflis DN; Rey NA; Venugopal-Lavanya H; Sewell B; Mitchell-Dick A; Clements KN; Milo S; Benkert AR; Rosales A; Fergione S; Asokan A
    Nat Commun; 2024 Mar; 15(1):2325. PubMed ID: 38485709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient RNA Virus Targeting via CRISPR/CasRx in Fish.
    Wang Q; Liu Y; Han C; Yang M; Huang F; Duan X; Wang S; Yu Y; Liu J; Yang H; Lu D; Zhao H; Zhang Y; Qin Q
    J Virol; 2021 Sep; 95(19):e0046121. PubMed ID: 34287045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing noncanonical crRNA for highly efficient genome editing.
    Xun G; Zhu Z; Singh N; Lu J; Jain PK; Zhao H
    Nat Commun; 2024 May; 15(1):3823. PubMed ID: 38714643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmable RNA base editing with photoactivatable CRISPR-Cas13.
    Yu J; Shin J; Yu J; Kim J; Yu D; Heo WD
    Nat Commun; 2024 Jan; 15(1):673. PubMed ID: 38253589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Applications of CRISPR/Cas13-Based RNA Editing in Plants.
    Kavuri NR; Ramasamy M; Qi Y; Mandadi K
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RNA editing with CRISPR-Cas13.
    Cox DBT; Gootenberg JS; Abudayyeh OO; Franklin B; Kellner MJ; Joung J; Zhang F
    Science; 2017 Nov; 358(6366):1019-1027. PubMed ID: 29070703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Massively parallel Cas13 screens reveal principles for guide RNA design.
    Wessels HH; Méndez-Mancilla A; Guo X; Legut M; Daniloski Z; Sanjana NE
    Nat Biotechnol; 2020 Jun; 38(6):722-727. PubMed ID: 32518401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells.
    Cui J; Techakriengkrai N; Nedumpun T; Suradhat S
    Sci Rep; 2020 Jun; 10(1):9617. PubMed ID: 32541822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and Evaluation of Guide RNA Transcripts with a 3'-Terminal HDV Ribozyme to Enhance CRISPR-Based Gene Inactivation.
    Berkhout B; Gao Z; Herrera-Carrillo E
    Methods Mol Biol; 2021; 2167():205-224. PubMed ID: 32712922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmable RNA targeting with CRISPR-Cas13.
    Shi P; Wu X
    RNA Biol; 2024 Jan; 21(1):1-9. PubMed ID: 38764173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
    Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
    Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmable RNA-Guided RNA Effector Proteins Built from Human Parts.
    Rauch S; He E; Srienc M; Zhou H; Zhang Z; Dickinson BC
    Cell; 2019 Jun; 178(1):122-134.e12. PubMed ID: 31230714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 82.